Title:
Treatment and Prophylaxis of VTE in Patients with Cancer: Putting the 2016 International Guidelines into Clinical Practice
Release Date:
January 24, 2017
Expiration Date:
January 23, 2018
Topics:
Hematology, Internal Medicine, Oncology, Vascular Medicine
Primary Audiences:
Oncologists, hematologists, internists, and other specialists and family physicians with an interest in thrombosis in patients with cancer
Activity Format:
Patient Case Studies
Credits:
Up to 5 (five) Section 1 credits under the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada

Needs Assessment

To consult the Needs Assessment, click here.

Activity Abstract

There is an increased risk of venous thromboembolism (VTE) in cancer patients. In fact, VTE is the most common complication and the second most common cause of death in patients with cancer. Surgery, systemic anti-cancer therapy, and metastasis can increase the risk of VTE. This case-based educational program has four modules, including an up-to-date overview of VTE in patients with cancer and three challenging clinical scenarios. Learners will have the opportunity to earn CME credit for each module they choose to complete. All modules include recommendations from the 2016 International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer, and provide appropriate treatment and prevention strategies. Learners will be able to follow their own knowledge gains and improvements in clinical competence by completing Practice Assessments, whereby they will review data from their patients with a diagnosis of cancer and thrombosis at various touch points.

Learning Objectives

Module 1. Overview of Treatment and Prophylaxis of VTE in Patients With Cancer: Putting the 2016 International Guidelines Into Clinical Practice
At the end of this module, participants will be able to:
  • Describe the mechanisms and clinical presentations that contribute to the increased incidence of VTE (DVT and PE) in patients with cancer
  • Determine risk factors for VTE in patients with cancer, including those undergoing surgery, receiving systemic anti-cancer therapy, and/or having a central venous catheter
  • Identify and apply appropriate prophylaxis and treatment of VTE, including CAT, in patients with cancer, as recommended by the International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

Module 2. Breast Cancer: The Case of Mrs. F
At the end of this module, participants will be able to:
  • Describe the risk of VTE (DVT or PE) in patients with cancer
  • Explain the anticoagulation protocol when a tumor biopsy is planned for a patient currently on a DOAC
  • Identify appropriate long-term treatment of VTE/ prevention of recurrence in patients with metastatic breast cancer undergoing chemotherapy

Module 3. Colon Cancer: The Case of Mr. V
At the end of this module, participants will be able to:
  • Describe the risk of VTE (DVT or PE) in surgical and medical patients with cancer
  • Explain the prophylaxis protocol when a colectomy is planned for a patient with colon cancer
  • Identify appropriate long-term treatment of VTE and prevention of recurrence in a patient with colon cancer undergoing chemotherapy

Module 4. Lung Cancer: The Case of Mrs. C
At the end of this module, participants will be able to:
  • Describe the risk of VTE, including central venous related thrombosis (CRT), in patients with cancer
  • Based on International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer (2016):
    • Explain the recommended prophylaxis protocol for a patient with lung cancer undergoing surgery
    • Identify appropriate prophylaxis and treatment of CRT in a patient with lung cancer

Faculty and Disclosures

Pr. Dominique Farge-Bancel (France)
Professor of Internal Medicine and Vascular Disease, St Louis Hospital, APHP, Paris 7 University, France
Professor Farge has been a member of an advisory board or similar committee for Aspen Pharmacare (2015) and Pfizer (2014), and has received a grant(s), an honorarium, or consultation fee(s) from Aspen Pharmacare (2015), Pfizer (2013-2014), and Sanofi (2009). Professor Farge also has participated in a clinical trial for LEO Pharma (2012-2014).

Pr. James Douketis (Canada)
Professor, Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Canada
Associate Director, Clinical Teaching Unit, St. Joseph's Hospital, Hamilton, Canada
Professor Douketis has been a member of an advisory board or similar committee for AstraZeneca (prior to 2008), Boehringer Ingelheim (2010-2012), Bayer (2010-2014), Biotie (2013), Bristol Myers-Squibb (2012-2014), Pfizer (2011-2014), Portola (2012), Sanofi (2014), and The Medicines Company (2012-2013), and has been a consultant to AGEN Biomedical (2004-2006), Boehringer Ingelheim (2009-2010), and Ortho-Janssen Pharmaceuticals (2007-2008). Professor Douketis has received grant support from Boehringer Ingelheim (2014).

Sponsoring Organization

This CME/CPD activity is sponsored by the not-for-profit professional organization ITAC-CME.

Accreditation and Credit Designation

This program meets the accreditation criteria as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and has been accredited by the Office of Continuing Professional Development, Faculty of Medicine, McGill University for up to 5 Section 1 credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Each physician should claim only credit commensurate with the extent of their participation in the activity.

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity.

Learners should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, Learners must complete the activity online during the valid credit period that is noted on the title page.

Instructions for Claiming Credits

Note that the credit you receive is based on your user profile.

  1. Read the target audience, learning objectives, and author disclosures on this page.
  2. Before you study your first selected module, you would like to study,must complete a Practice Assessment of at least one patient who has a diagnosis of cancer and venous thromboembolism from your clinical practice. You may complete assessments for up to three patients who fit this clinical profile. This collected data will be anonymized and aggregated to inform the future development of clinical practice guidelines on the topic of women, thrombosis, and cancer.
  3. Prior to studying a module, you must complete the pre-activity test associated with the module.
  4. Study the educational content of each module you would like to complete.
  5. Complete the post-activity test at the end of each module you choose to study. You must receive a passing score (75% or higher) in order to receive a Certificate of Completion and claim credit.
  6. Complete the activity Evaluation for the module to provide feedback for future programming.
  7. Click “Claim Credit” and follow the instructions to print out the Certificate of Completion. Note that you cannot alter the Certificate. Keep this Certificate in your files.

Hardware/Software Requirements

To access this activity, Learners will need:

  • A computer with an Internet connection
  • The latest version of Google Chrome
  • Adobe Acrobat Reader
  • An HTML5-capable browser

More Information

For questions regarding the content of this activity, contact info@cmesolutions.com.

Technical Assistance

For technical assistance, contact tech-help@cmesolutions.com.